IMR Press / EJGO / Volume 24 / Issue 6 / pii/2003218

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Hormonal replacement therapy and evaluation of intrauterine pathology in postmenopausal women: a ten-year study

Show Less
1 Department of Gynecological Sciences, Perinatology and Child Health II School of Medicine, University of Rome “La Sapienza”, Rome, Italy
Eur. J. Gynaecol. Oncol. 2003, 24(6), 507–512;
Published: 10 December 2003

Background: To evaluate the role of hormonal replacement therapy (HRT) in determining: a) abnormal uterine bleeding (AUB); b) increased endometrial thickness at transvaginal sonography (TVS); c) the correct indication for outpatient hysteroscopy (HS) and biopsy in diagnosing intrauterine pathology.Methods: Between April 1991 and April 2001 a group of 3,400 postmenopausal women was referred to the Department of Obstet­rics and Gynecology of Rome University “La Sapienza”; 16.7% of them had received HRT. 587 out of the 3,400 women were recruited for a comparative study, including four groups. To assess statistical significance of HRT in determining AUB, and/or endometrial thickness related to malignant disease the chi-square test was used; p < 0.05 was considered significant. Histology was considered the true result (control). Results: An increase in the endometrial thickness occurred significantly more often in women on HRT (p < 0.03); as well as the percentage of AUB (p < 0.0001). No difference in the incidence of endometrial adenocarcinoma was reported between the HRT and the non HRT groups. Conclusions: In postmenopausal women using HRT we can confirm that a higher incidence of signs (AUB, endometrial thick­ness ≥5 mm) does not coincide with a higher incidence of malignant pathology. The data obtained from the recruited patients was arranged and evaluated by the most suitable methods for screening endometrial adenocarcinoma. According to our experience, we believe a cut-off point of 8 mm to be significant (p < 0.001) to perform an hysteroscopy and biopsy except for asymptomatic patients on HRT.

Endometrial adenocarcinoma
Back to top